点阵二氧化碳激光对眶周皮肤年轻化有效性、 安全性和满意度的系统综述及荟萃分析

袁 悦1 ，纪晓晖1 ，顾敬喜2 ，陈官芝1*

1 青岛大学附属医院皮肤科，山东 青岛

2 山东省郯城县皮肤病防治站，山东 临沂

收稿日期：2024年2月27日；录用日期：2024年3月21日；发布日期：2024年3月29日

摘 要

目的：点阵CO₂激光疗法在改善皮肤老化方面已经得到了广泛的应用，由于眶周皮肤的脆弱、易造成瘢痕的特性，目前针对眶周皮肤年轻化的激光治疗开展较少。本研究旨在确定点阵CO₂激光联合疗法在眶周皮肤再生表面修复中的有效性和安全性。方法：截至2023年12月01号，在3个主要数据库中进行了系统搜索。纳入的研究包括点阵CO₂激光或联合其他疗法来改善眼周老化的有效性及并发症，并报告了治疗的有效性和安全性；多篇文章报道同一组患者时，选择最近的报道完整数据的文章。排除标准包括体外研究、动物研究、未使用点阵CO2激光、专家述评、书信、会议摘要、数据不完整或不能获取、CO2点阵激光治疗但未声明关于眶周皱纹或年轻化的研究。结果：筛选后纳入7项临床试验，共纳入166例患者。研究汇总发现眶周皮肤老化及皱纹深度绝大部分都得到了改善，大多数患者都对这项技术感到满意。研究中发现患者在CO2激光术后耐受性良好，主要产生的并发症有包括红斑(n = 8)、色素沉着过度(n = 8)、渗出、渗血、局部水肿、结痂、疼痛、灼热、瘙痒、水疱等。随访时均再未观察到疱疹感染等其他不良反应。术后7天无瘢痕及表皮萎缩再形成。大多数并发症轻微且短暂。治疗后红斑发生率为0.10 (95% CI:0.03~0.18, p < 0.01)，色素沉着发生率为0.08 (95% CI: 0.03~0.16, p < 0.01)。结论：研究发现，点阵CO2激光治疗眶周皮肤年轻化是有效且安全的。由于缺乏高质量的报告，有必要进行更多的试验来证实这些结果。

关键词 年轻化，点阵CO₂ 激光，眶周，Meta分析

A Systematic Review and Meta-Analysis of Efficacy, Safety, and Satisfaction Rates of Fractional CO₂ Laser in Periocular Skin Rejuvenation

Yue Yuan1, Xiaohui Ji1, Jingxi Gu2, Guanzhi Chen1*

1 Dermatology Department, The Affiliated Hospital of Qingdao University, Qingdao Shandong

2 Skin Disease Prevention Station of Tancheng County, Shandong Province, Linyi Shandong Received: Feb. 27th, 2024; accepted: Mar. 21st , 2024; published: Mar. 29th, 2024

Abstract

Objective: Fractional CO₂ laser therapy has been widely used in improving skin aging. Due to the fragile and scarring properties of periorbital skin, laser therapy for periorbital skin rejuvenation is rarely carried out now. The aim of this study was to determine the efficacy and safety of fractional CO₂ laser combined therapy in periorbital skin regeneration surface repair. Methods: As of December 01, 2023, a systematic search was conducted in three major databases. Included studies included the efficacy and complications of fractional CO₂ laser or combined with other therapies to improve periocular aging, and reported the efficacy and safety of the treatment. When multiple articles report on the same group of patients, select the most recent article reporting completedata. Exclusion criteria included in vitro studies, animal studies, no use of a fractional CO₂ laser, expert reviews, letters, conference abstracts, incomplete or unavailable data, and studies on periorbital wrinkles or rejuvenation that did not claim fractional CO₂ laser treatment. Results: After screening, 7 clinical trials were included, involving a total of 166 patients. The study summary found that periorbital skin aging and wrinkle depth were largely improved, and most patients were satisfied with this treatment. The study found that patients were well tolerated after fractional CO₂ laser surgery, and the main complications included erythematosis (n = 8), hyper pigmentation (n = 8), exudation, bleeding, local edema, scab, pain, burning, pruritus, blisters, etc. No other adverse reactions such as herpes infection were observed during follow-up. No scar or epidermal atrophy was found 7 days after surgery. Most complications were mild and short-lived. The incidence of erythema after treatment was 0.10 (95% CI: 0.03~0.18, p < 0.01), and the incidence of hyper pigmentation was 0.08 (95% CI: 0.03~0.16, p < 0.01). Conclusion: It is found that fractional CO₂ laser is effective and safe in the treatment of periorbital skin rejuvenation. Due to paucity of high-quality reportings, additional trials are warranted to corroborate these results.

Keywords Rejuvenation, Fractional CO₂ Laser, Periorbital, Meta-Analysis

Copyright © 2024 by author(s) and Hans Publishers Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

Hallmarks of aging: An expanding universe（2023）--3

Hallmarks of aging: An expanding universe（2023）--2

To be continued.

Hallmarks of aging: An expanding universe（2023）--1

Carlos Lo´ pez-Otı´n,1,2,3,* Maria A. Blasco,4 Linda Partridge,5,6 Manuel Serrano,7,8,9 and Guido Kroemer10,11,12,*

1 Departamento de Bioquı´mica y Biologı´a Molecular, Instituto Universitario de Oncologı´a (IUOPA), Universidad de Oviedo, Oviedo, Spain

2 Instituto de Investigacio´ n Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain

3 Centro de Investigacio´ n Biome´ dica en Red de Ca´ ncer (CIBERONC), Madrid, Spain

4 Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain

5 Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London, UK

6 Max Planck Institute for Biology of Ageing, Cologne, Germany

7 Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain

8 Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain

9 Altos Labs, Cambridge, UK

10 Centre de Recherche des Cordeliers, Equipe labellise´ e par la Ligue contre le cancer, Universite´ de Paris, Sorbonne Universite´ , INSERM U1138, Institut Universitaire de France, Paris, France

11 Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France

12 Institut du Cancer Paris CARPEM, Department of Biology, Hoˆ pital Europe´ en Georges Pompidou, AP-HP, Paris, France

*Correspondence: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (C.L.-O.), 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (G.K.)

https://doi.org/10.1016/j.cell.2022.11.001

SUMMARY

Aging is driven by hallmarks fulfilling the following three premises: (1) their age-associated manifestation, (2) the acceleration of aging by experimentally accentuating them, and (3) the opportunity to decelerate, stop, or reverse aging by therapeutic interventions on them. We propose the following twelve hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. These hallmarks are interconnected among each other, as well as to the recently proposed hallmarks of health, which include organizational features of spatial compartmentalization, maintenance of homeostasis, and adequate responses to strees.

Reprogramming to recover youthful epigenetic information and restore vision

Yuancheng Lu1, Benedikt Brommer2,3,11, Xiao Tian1,11, Anitha Krishnan3,4,11, Margarita Meer5,6,11, Chen Wang2,3, Daniel L. Vera1, Qiurui Zeng1, Doudou Yu1, Michael S. Bonkowski1, Jae-Hyun Yang1, Songlin Zhou2,3, Emma M. Hoffmann3,4, Margarete M. Karg3,4, Michael B. Schultz1, Alice E. Kane1, Noah Davidsohn7, Ekaterina Korobkina3,4, Karolina Chwalek1, Luis A. Rajman1, George M. Church7, Konrad Hochedlinger8, Vadim N. Gladyshev5, Steve Horvath9, Morgan E. Levine6, Meredith S. Gregory-Ksander3,4,* , Bruce R. Ksander3,4,* , Zhigang He2,3,* , David A. Sinclair1,10,*,#

1. Department of Genetics, Blavatnik Institute, Paul F. Glenn Center for Biology of Aging Research, Harvard Medical School, MA, USA;

2. Department of Neurology, Boston Children’s Hospital, Harvard Medical School, MA, USA;

3. Department of Ophthalmology, Harvard Medical School, Boston, MA, USA;

4. Schepens Eye Research Institute of Mass Eye & Ear, Harvard Medical School, MA, USA;

5. Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, MA, USA;

6. Department of Pathology, Yale School of Medicine, New Haven, CT, USA;

7. Department of Genetics, Wyss Institute for Biologically Inspired Engineering, Harvard University, MA, USA;

8. Department of Molecular Biology, Cancer Center and Center for Regenerative Medicine, Massachusetts General Hospital, MA, USA;

9. Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, CA, USA;

10. Laboratory for Aging Research, Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, Australia;

11. These authors contributed equally: B. B., X. T., A. K., M. M.;

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

#* Correspondence: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。.

Senior authors;

Contributions

Y.L. and D.A.S. conceived the project. Y.L., X.T., and D.A.S. wrote the manuscript with input from all co-authors. Y.L. was involved in all experiments and analyses. M.S.B. and J.-H.Y. provided early training to Y.L.. B.B., C.W., Q.Z., D.Y., S.Z., and Z.H. contributed to the optic nerve crush studies and imaging. A.K., D.Y., Q.Z., E.M.H., E.K., M.S.G.-K., and B.R.K. contributed to the glaucoma and ageing studies. M.M.K. and B.R.K. performed OCT imaging and analysis. M.M. and V.N.G. conducted ribosomal DNAm age analysis for mouse RGCs. M.E.L. developed DNAm ageing signature. D.L.V. performed the RNA-seq and gene association analysis. X.T. conducted human neuron experiments. S.H. conducted human methylation clock analysis. X.T., J.-H.Y., and K.H. helped with transgenic mouse fibroblasts work. M.S.B., X.T., M.B.S., A.E.K., L.A.R., helped with systemic AAV9 experiments. N.D., and G.M.C. helped with plasmid constructs and AAV9 production. K.C. helped with grant applications and project management. M.S.G.-K., B.R.K., Z.H., and D.A.S. jointly supervised this work.

Conflict of interest

D.A.S. is a consultant to, inventor of patents licensed to, board member of and equity owner of Iduna Therapeutics, a Life Biosciences company developing epigenetic reprograming therapies. D.A.S. is an advisor to Zymo Research, an epigenetics tools company. Additional disclosures are at https://genetics.med.harvard.edu/sinclair/people/sinclair-other.php. Y.L., L.A.R. and S.H. are equity owners of Iduna Therapeutics, a Life Biosciences company. D.L.V. is an advisor to Liberty Biosecurity. M.S.B. is a shareholder in MetroBiotech. K.C. is an equity owner in Life Biosciences and affiliates. N.D. and G.M.C. are co-founders of Rejuvenate Bio. Disclosures for G.M.C. can be found at http://arep.med.harvard.edu/gmc/tech.html. M.E.L. is a bioinformatics advisor to Elysium Health. Y.L., N.D. and D.A.S. are inventors on patents arising from this work (WO/2020/069373 and WO/2020/069339), filed by the President and Fellows of Harvard College. The other authors declare no competing interests.

男性雄激素性秃发中西医诊疗专家共识

国家皮肤和性传播疾病专业质控中心毛发专家委员会,国家中西医结合医学中心毛发专病医联体,中国整形美容协会中医美容分会,中华中医药学会皮肤科分会毛发学组,北京中西医结合学会皮肤性病专业委员会毛发学组

National Professional Quality Control Center for Skin and Sexually Transmitted Diseases, Hair Expert Comittee; National Center of Integrated Traditional Chinese and Westerm Medicine Hair Diseases Medical Treatment Combination; Chinese Plastic and Aesthetic Association of Traditional Chinese Medicine Cosmetology Branch; Working Group for Hair Diseases, China Association of Chinese Medicine, Dermatology Branch; Working Group for Hair Diseases, Beijing Association of the Integrating of Traditional and Western Medicine Dematological and Venereal Diseases Professional Committee

[摘要]雄激素性秃发(AGA)是临床最常见的脱发性疾病,男性AGA发病率更高,严重影响患者的身心健康和生活质量。目前认为该病与遗传易感性和脱发部位毛囊细胞对雄激素的高反应性密切相关。诊断主要依据病史、脱发模式和皮肤镜检查。中医药治疗是我国AGA防治的优势和特色,为了推广男性AGA的规范化中西医诊治理念,提高我国在该领域的诊治水平,特组织编写了该专家共识。

[关键词]雄激素性秃发,男性; 中西医;诊疗;专家共识
[中图分类号] R758.71
[文献标识码] A
[文章编号] 1000- 4963(2024 )05- -0305-07
doi: 10.16761/j.cnki.1000- 4963.2024.05.014